Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her-2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT03644589
What this trial is testing

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeMetastatic Breast Cancer+3 more
University of Washington
Not applicableStudy completedNCT06636591
What this trial is testing

Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer

Who this might be right for
Breast Cancer FemaleHER2-negative Breast Cancer
Fudan University 14
Testing effectiveness (Phase 2)Looking for participantsNCT07483307
What this trial is testing

The Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerHER2 Negative Breast Carcinoma+2 more
Memorial Sloan Kettering Cancer Center 176
Early research (Phase 1)Study completedNCT04572295
What this trial is testing

E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Eisai Co., Ltd. 51
Large-scale testing (Phase 3)Enrolling By InvitationNCT05645536
What this trial is testing

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Who this might be right for
Breast Cancer
Tolmar Inc. 250
Testing effectiveness (Phase 2)Study completedNCT02102490
What this trial is testing

Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 132
Not applicableStudy completedNCT07072013
What this trial is testing

An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 1,937
Testing effectiveness (Phase 2)Study completedNCT00463788
What this trial is testing

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

Who this might be right for
Breast Neoplasm
Merck KGaA, Darmstadt, Germany 181
Testing effectiveness (Phase 2)Study completedNCT01730612
What this trial is testing

ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA

Who this might be right for
HER2 Negative Breast Carcinoma Expressing CEA
Nantes University Hospital 23
Not applicableNot Yet RecruitingNCT07553234
What this trial is testing

Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment

Who this might be right for
Breast Cancer
University of Chicago 20
Not applicableStudy completedNCT05132101
What this trial is testing

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Who this might be right for
Metastatic Breast Cancer
Pfizer 2,758
Testing effectiveness (Phase 2)UnknownNCT05044988
What this trial is testing

HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Who this might be right for
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Testing effectiveness (Phase 2)Looking for participantsNCT06516289
What this trial is testing

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Who this might be right for
BRCA-Mutated Breast CarcinomaHER2-negative Breast Cancer
Fudan University 130
Large-scale testing (Phase 3)Study completedNCT03337724
What this trial is testing

Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 579
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07767474
What this trial is testing

Evaluate ATX-898 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Antares Therapeutics, Inc 343
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06462079
What this trial is testing

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Who this might be right for
Brain Metastasis
Guangzhou Medical University 43
Testing effectiveness (Phase 2)Study completedNCT01904903
What this trial is testing

Cardiac Safety Study in Patients With HER2 + Breast Cancer

Who this might be right for
HER2 Positive Breast CancerLeft Ventricular Function Systolic Dysfunction
Medstar Health Research Institute 31
Testing effectiveness (Phase 2)Study completedNCT05659563
What this trial is testing

Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%

Who this might be right for
Breast CancerBreast Cancer, Early-Onset
MedSIR 92
Testing effectiveness (Phase 2)Ended earlyNCT01729884
What this trial is testing

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
University of Washington 3
Next Page